Idexx Laboratories reports Q4 EPS $2.32 with items, consensus $2.12

Q4 EPS included 4c per share negative impact from currency changes, 2c per share in tax benefits from share-based compensation and a benefit of 10c per share from the release of tax valuation allowances. Reports Q4 revenue $902M, consensus $891.25M. “Outstanding execution by IDEXX’s commercial and operations teams supported delivery of strong organic revenue growth and financial results for the Company in 2023. We’re excited about our sustained business momentum, supported by partnerships with our customers, that will be further enabled by key innovations we are advancing across our instrument platforms, test menu and software offerings. This includes the launch of our new revolutionary slide-free cellular analyzer, IDEXX inVue Dx targeted for late 2024,” said Jay Mazelsky, CEO. “Our performance and progress demonstrate that customers of all types appreciate the purpose-built solutions that we provide and utilize these tools and services to deliver increased standards of care while realizing critical efficiency gains.”